Skip to content
value.today

Sagimet Biosciences Inc.

SGMT
$744 Mmarket cap on Oct 30, 2026+520.3% since Jan 2024
Compare
World rank
#10,758
Revenue
—
For year ending December-2025
Net income
$-51 M
SEC filing
Employees
16
As of December 31, 2025
SEC filing

Sagimet Biosciences Inc. in brief

Sagimet Biosciences Inc. is a listed company in the Biotechnology industry, based in Foster City, California, USA. Its market value was $744 M on 30 October 2026, which makes it the 10,758th largest listed company in the world and the 2,254th largest in the USA on this site. It employs about 16 people and David Happel is its chief executive. Its shares trade under the symbol SGMT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Sagimet Biosciences Inc.

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne.

The critical role of FASN overactivity in MASH makes it an attractive target for drug therapy. Our FASN inhibitor, denifanstat, targets multiple drivers of MASH by reducing steatosis, inflammation and fibrosis.

From the company's annual report filed with the US SEC: read the report

Sagimet Biosciences Inc. timeline

3 events, 2007–2023
  1. 2007
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. ✎
    Renamed Sagimet Biosciences Inc.
    Formerly 3-V Biosciences, Inc..
  5. 2023
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 17 July 2023; shares registered for exchange trading on 11 July 2023.

Events of Sagimet Biosciences Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$201 M$402 M$603 M$804 M202420252026

World rank over time

▲ up 10,053 places since 2023
2023-07-30: #20829#20,82920232024-01-05: #20492#20,49220242026-03-08: #9169#9,16920262026-08-01: #11216#11,21620262026-10-13: #11679#11,67920262026-10-30: #10776#10,7762026

Rank in USA: #4,071 (Jul 2023) · #3,578 (Jan 2024) · #1,753 (Mar 2026) · #2,365 (Aug 2026) · #2,397 (Oct 2026) · #2,256 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
6.7×
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-45.8%
Liabilities / assets
4.4%
R&D / revenue
989.0%
Profit per employee
$-3.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2022: revenue —, net income $-31M—FY22Fiscal year ending Dec 2023: revenue $2M, net income $-28M$2MFY23Fiscal year ending Dec 2024: revenue —, net income $-46M—FY24Fiscal year ending Dec 2025: revenue —, net income $-51M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-57M$-51M—
Dec 2024——$-54M$-46M—
Dec 2023$2M—$-31M$-28M-1394.0%
Dec 2022——$-31M$-31M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-46M——$-1.58—
Dec 2024$-42M——$-1.45—
Dec 2023$-24M——$-2.66—
Dec 2022$-24M——$-165.20—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue —, net income $-18M—Mar ’25Three months to Jun 2025: revenue —, net income $-10M—Jun ’25Three months to Sep 2025: revenue —, net income $-13M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-10M—Dec ’25Three months to Mar 2026: revenue —, net income $-11M—Mar ’26Three months to Jun 2026: revenue —, net income $-14M—Jun ’26Three months to Sep 2026: revenue —, net income $-19M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-19M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Sagimet Biosciences Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-57 M
Net income
$-51 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$116 M
Total liabilities
$5 M
Total equity
$111 M

As of December-2025

Top 100 institutional investors in Sagimet Biosciences Inc.#

As of Sep 30, 2026
153 institutions held 69.7 M shares (about 97.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 51.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Sagimet Biosciences Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.6,970,208+394,420 (+6.00%)9.77%$69 MNov 13, 2026
2Balyasny Asset Management L.P.5,542,492+1,916,379 (+52.85%)7.77%$55 MNov 16, 2026
3Silverarc Capital Management, LLC3,745,990+818,292 (+27.95%)5.25%$37 MNov 12, 2026
4BVF Inc/il3,500,000+1,000,000 (+40.00%)4.90%$35 MNov 16, 2026
5Woodline Partners LP3,143,952+143,300 (+4.78%)4.41%$31 MNov 16, 2026
6Federated Hermes, Inc.3,093,603+1,006,888 (+48.25%)4.33%$31 MNov 12, 2026
7Caligan Partners LP2,794,484+294,484 (+11.78%)3.92%$28 MNov 16, 2026
8Commodore Capital LP2,757,742New3.86%$27 MNov 16, 2026
9Vanguard Capital Management LLC2,626,548+60,276 (+2.35%)3.68%$26 MNov 13, 2026
10Affinity Asset Advisors, LLC2,527,384+29,520 (+1.18%)3.54%$25 MNov 13, 2026
11State Street Corp2,427,837+432,745 (+21.69%)3.40%$24 MNov 12, 2026
12Saturn V Capital Management LP2,002,813+522,895 (+35.33%)2.81%$20 MNov 16, 2026
13Great Point Partners LLC1,961,701-68,232 (-3.36%)2.75%$19 MNov 16, 2026
14Ameriprise Financial Inc1,900,603+1,319,386 (+227.00%)2.66%$19 MNov 16, 2026
15Ra Capital Management, L.P.1,800,000New2.52%$18 MNov 16, 2026
16Geode Capital Management, LLC1,543,687+99,668 (+6.90%)2.16%$15 MNov 6, 2026
17Aberdeen Group plc1,475,078+627,378 (+74.01%)2.07%$15 MNov 10, 2026
18Spruce Street Capital LP1,400,000New1.96%$14 MNov 13, 2026
19Blue Owl Capital Holdings LP1,125,544-135,000 (-10.71%)1.58%$11 MNov 13, 2026
20Adage Capital Partners GP, L.L.C.1,111,200New1.56%$11 MNov 16, 2026
21D. E. Shaw & Co., Inc.1,037,706+1,015,529 (+4579.20%)1.45%$10 MNov 16, 2026
22Marshall Wace, LLP752,365New1.05%$7 MNov 13, 2026
23Driehaus Capital Management LLC727,150+560,483 (+336.29%)1.02%$7 MNov 16, 2026
24Atom Investors LP725,924+379,906 (+109.79%)1.02%$7 MNov 16, 2026
25Goldman Sachs Group Inc568,526-190,560 (-25.10%)0.80%$6 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Sagimet Biosciences Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Dimensional Fund Advisors LP527,478+129,506 (+32.54%)0.74%$5 MNov 4, 2026
27Boothbay Fund Management, LLC518,764+54,669 (+11.78%)0.73%$5 MNov 16, 2026
28J. Goldman & Co LP508,402New0.71%$5 MNov 16, 2026
29Jones Hill Capital LP502,587New0.70%$5 MNov 13, 2026
30Vanguard Portfolio Management LLC495,817+92,335 (+22.88%)0.69%$5 MNov 13, 2026
31Northern Trust Corp482,434+14,049 (+3.00%)0.68%$5 MNov 16, 2026
32Nantahala Capital Management, LLC471,831New0.66%$5 MNov 13, 2026
33UBS Group AG440,911+100,981 (+29.71%)0.62%$4 MNov 10, 2026
34Seven Fleet Capital Management LP429,113+25,568 (+6.34%)0.60%$4 MNov 16, 2026
35Vanguard Fiduciary Trust Co425,613+24,775 (+6.18%)0.60%$4 MNov 13, 2026
36Superstring Capital Management LP423,006New0.59%$4 MNov 16, 2026
37Millennium Management LLC406,857-530,168 (-56.58%)0.57%$4 MNov 16, 2026
38Farallon Capital Management, L.L.C.400,000-15,000 (-3.61%)0.56%$4 MNov 16, 2026
39Morgan Stanley341,663+239,436 (+234.22%)0.48%$3 MNov 13, 2026
40Raymond James Financial Inc338,821+6,798 (+2.05%)0.47%$3 MNov 12, 2026
41Bank Of America Corp /de/321,139+177,455 (+123.50%)0.45%$3 MNov 16, 2026
42Rock Springs Capital Management LP315,458+65,458 (+26.18%)0.44%$3 MNov 16, 2026
43Walleye Capital LLC307,785New0.43%$3 MNov 13, 2026
44AWM Investment Company, Inc.300,000+220,000 (+275.00%)0.42%$3 MNov 13, 2026
45BNP Paribas Financial Markets258,125+138,089 (+115.04%)0.36%$3 MNov 12, 2026
46Palo Alto Investors LP250,0000 (0.00%)0.35%$2 MNov 16, 2026
47Bank of New York Mellon Corp210,523+9,875 (+4.92%)0.29%$2 MNov 5, 2026
48Wellington Management Group LLP205,892+165,092 (+404.64%)0.29%$2 MNov 16, 2026
49Barclays PLC202,396-25,535 (-11.20%)0.28%$2 MNov 6, 2026
50Acadian Asset Management LLC186,004New0.26%$2 MNov 9, 2026
51Charles Schwab Investment Management Inc175,873+1 (0.00%)0.25%$2 MNov 16, 2026
52Invesco Ltd.172,355+137,624 (+396.26%)0.24%$2 MNov 12, 2026
53XTX Topco Ltd166,874New0.23%$2 MNov 16, 2026
54Sofinnova Investments, Inc.162,380-4,287 (-2.57%)0.23%$2 MNov 16, 2026
55Nuveen, LLC134,413-6,224 (-4.43%)0.19%$1 MNov 10, 2026
56Citadel Advisors LLC133,079+28,446 (+27.19%)0.19%$1 MNov 16, 2026
57Caption Management, LLC110,898New0.16%$1 MNov 16, 2026
58FNY Investment Advisers, LLC109,350+100 (+0.09%)0.15%$1 MOct 16, 2026
59Susquehanna International Group, LLP100,018+89,068 (+813.41%)0.14%$1 MNov 16, 2026
60Prelude Capital Management, LLC97,000New0.14%$1 MNov 16, 2026
61RB Capital Management, LLC97,0000 (0.00%)0.14%$1 MNov 17, 2026
62Renaissance Technologies LLC89,700-257,227 (-74.14%)0.13%$1 MNov 12, 2026
63Rhumbline Advisers72,274-2,065 (-2.78%)0.10%$1 MNov 10, 2026
64Perceptive Advisors LLC67,674New0.09%$1 MNov 16, 2026
65Kestra Advisory Services, LLC66,4140 (0.00%)0.09%$1 MNov 2, 2026
66Inspire Investing, LLC62,477New0.09%$1 MOct 22, 2026
67ACT Capital Partners, L.P.60,000—0.08%$1 MNov 6, 2026
68Rafferty Asset Management, LLC54,836+27,510 (+100.67%)0.08%$1 MNov 13, 2026
69Persistent Asset Partners Ltd52,677+42,308 (+408.02%)0.07%$1 MNov 13, 2026
70Deutsche Bank AG\51,016-7,186 (-12.35%)0.07%$1 MNov 6, 2026
71Hudson Bay Capital Management LP49,7830 (0.00%)0.07%$0 MNov 13, 2026
72Price T Rowe Associates Inc /MD/48,8830 (0.00%)0.07%$0 MNov 16, 2026
73Two Sigma Investments, LP47,502-34,400 (-42.00%)0.07%$0 MNov 16, 2026
74Trexquant Investment LP42,802New0.06%$0 MNov 16, 2026
75Vanguard Global Advisers, LLC38,369+16,611 (+76.34%)0.05%$0 MNov 13, 2026
76Bridgeway Capital Management, LLC37,337-184,204 (-83.15%)0.05%$0 MNov 16, 2026
77Jpmorgan Chase & Co35,874+6,944 (+24.00%)0.05%$0 MNov 12, 2026
78MetLife Investment Management, LLC35,6820 (0.00%)0.05%$0 MNov 16, 2026
79Point72 Asset Management, L.P.35,629New0.05%$0 MNov 16, 2026
80Empowered Funds, LLC33,237New0.05%$0 MNov 13, 2026
81MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.32,299+2,182 (+7.25%)0.05%$0 MNov 16, 2026
82HRT Financial LP31,614New0.04%$0 MNov 13, 2026
83Gsa Capital Partners LLP30,453New0.04%$0 MNov 16, 2026
84Wells Fargo & Company/mn26,308-37,688 (-58.89%)0.04%$0 MNov 16, 2026
85Los Angeles Capital Management LLC25,687New0.04%$0 MNov 12, 2026
86Citigroup Inc25,376-27,463 (-51.97%)0.04%$0 MNov 4, 2026
87Connective Capital Management, LLC25,000New0.04%$0 MNov 16, 2026
88Quantinno Capital Management LP24,453New0.03%$0 MNov 13, 2026
89Alliancebernstein L.P.23,360+5,160 (+28.35%)0.03%$0 MNov 16, 2026
90Cresset Asset Management, LLC23,079+3,000 (+14.94%)0.03%$0 MNov 16, 2026
91Squarepoint Ops LLC22,441New0.03%$0 MNov 9, 2026
92LPL Financial LLC21,920-4,830 (-18.06%)0.03%$0 MNov 6, 2026
93Composition Wealth, LLC21,3760 (0.00%)0.03%$0 MNov 10, 2026
94SummitTX Capital, L.P.20,159-2,553 (-11.24%)0.03%$0 MNov 16, 2026
95WINTON GROUP Ltd20,000New0.03%$0 MNov 12, 2026
96Profund Advisors LLC19,737+5,234 (+36.09%)0.03%$0 MOct 29, 2026
97Entropy Technologies, LP18,426New0.03%$0 MNov 13, 2026
98Abacus Planning Group, Inc.18,0640 (0.00%)0.03%$0 MNov 2, 2026
99SEI Investments Co17,711+2,834 (+19.05%)0.02%$0 MNov 10, 2026
100RPG Investment Advisory, LLC17,3500 (0.00%)0.02%$0 MOct 21, 2026

All 153 institutional investors, with who bought and sold →

Mutual funds holding Sagimet Biosciences Inc.#

89 funds hold shares worth $96 M (about 13.9% of the company). Since their previous reports 76 added shares and 0 sold, buying $64 M net.
Mutual funds holding Sagimet Biosciences Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company2.08 M$15 M2.3%0.52%no changeJul 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.86 M$14 M2.0%<0.01%+139%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.50 M$12 M1.6%0.01%newJun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.983,147$8 M1.1%0.07%newJun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.847,700$7 M0.93%0.95%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.659,000$5 M0.72%<0.01%+127%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC643,413$5 M0.70%0.01%newJul 31, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC585,181$4 M0.64%0.07%newMay 29, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors431,516$3 M0.47%0.02%newJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors413,328$3 M0.45%0.04%+118%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC301,060$2 M0.33%0.22%+37%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC290,427$2 M0.32%<0.01%+104%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors197,472$2 M0.22%0.10%+168%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.142,839$1 M0.16%0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP136,754$1 M0.15%<0.01%+30%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors118,725$1 M0.13%<0.01%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC109,843$1 M0.12%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC105,610$1 M0.12%<0.01%+125%May 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP101,803$1 M0.11%<0.01%+38%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC85,272$1 M0.09%<0.01%+123%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC78,077$1 M0.09%0.01%newJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust73,083$1 M0.08%0.02%+27%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC63,627$0 M0.07%0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP67,035$0 M0.07%<0.01%+93%Jul 31, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC52,449$0 M0.06%0.07%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC48,900$0 M0.05%0.26%no changeJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC47,683$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC43,060$0 M0.05%0.02%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation42,600$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC34,976$0 M0.04%0.07%newJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC33,403$0 M0.04%0.05%newJul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.30,398$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.33,033$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC32,776$0 M0.04%<0.01%+137%Jul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.26,856$0 M0.03%<0.01%+88%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC27,951$0 M0.03%0.01%newJul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.23,336$0 M0.03%<0.01%+83%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC20,225$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.19,417$0 M0.02%<0.01%+25%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC21,062$0 M0.02%<0.01%+126%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC17,984$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC18,571$0 M0.02%<0.01%+11%May 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC16,793$0 M0.02%0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.15,100$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC13,175$0 M0.01%0.05%+148%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC13,049$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS12,962$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC12,099$0 M0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC10,422$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.9,220$0 M0.01%0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC9,100$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC9,100$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.8,962$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC8,901$0 M<0.01%0.01%+116%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP8,721$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC7,916$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC7,018$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC6,911$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC6,881$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.6,764$0 M<0.01%<0.01%+127%Jul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC6,156$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management5,333$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS5,196$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,699$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP4,643$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC4,167$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,056$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS4,236$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC3,763$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,964$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC3,410$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP3,445$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust3,012$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,628$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP2,817$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP2,492$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP2,377$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC2,060$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,020$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC1,947$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP1,776$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,483$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,172$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,048$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC662$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC606$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC550$0 M<0.01%<0.01%+39%Jun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.488$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC327$0 M<0.01%<0.01%+122%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 89 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Sagimet Biosciences Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$4.9 M
10 sales, 5 insiders
Net, 12 months
-$4.9 M
open market only
Insiders on file
14
since
$64 K-$3.8 M$0Nov 2023: bought $1 K (1 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $7 K (1 trades), sold $0 (0 trades)Mar 2024: bought $64 K (1 trades), sold $0 (0 trades)MarJul 2024: bought $0 (0 trades), sold $178 K (4 trades)Jul 2025: bought $0 (0 trades), sold $772 K (3 trades)JulNov 2025: bought $0 (0 trades), sold $290 K (1 trades)Feb 2026: bought $0 (0 trades), sold $105 K (4 trades)FebJul 2026: bought $0 (0 trades), sold $719 K (3 trades)Aug 2026: bought $0 (0 trades), sold $3.8 M (2 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Sagimet Biosciences Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed George KembleDirectorOption exercise10b5-1 plan+326,618$6.360$2.1 M388,779Form 4
filed George KembleDirectorOption exercise10b5-1 plan+24,369$6.360$155 K413,148Form 4
filed George KembleDirectorSell10b5-1 plan-350,987$10.23$3.6 M62,161Form 4
filed George KembleDirectorOption exercise10b5-1 plan+9,751$6.360$62 K71,912Form 4
filed George KembleDirectorOption exercise10b5-1 plan+10,455$6.360$66 K82,367Form 4
filed George KembleDirectorSell10b5-1 plan-20,206$9.950$201 K62,161Form 4
filed David HappelPresident & CEO, DirectorSell-64,051$7.760$497 K741,570Form 4
filed George KembleDirectorSell10b5-1 plan-18,844$7.460$141 K62,161Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Sagimet Biosciences Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
12.2 M
10.47 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-79.48 reverse split

Trading halts

  • 2025-01-06 14:30 UTC, code LUDP, resumed 14:40 UTC

Fails to deliver

  • : 201 shares at $10.43
  • : 717 shares at $9.58
  • : 100 shares at $9.95
  • : 24,904 shares at $9.74
  • : 4,606 shares at $8.02

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Sagimet Biosciences Inc. scorecard#

Passes 1 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median6.7×Price to book 6.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.58 vs -1.45Diluted EPS -1.58 in fiscal 2025 against -1.45 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$51 MNet income -$51 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-38.2%-38.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities22.8×Current ratio 22.82 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year3.2%Diluted shares up 3.2% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Sagimet Biosciences Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Sagimet Biosciences Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022
Income statement
Revenue——2.0—
Research and development39382025
General and administrative1816136.1
Operating expenses57543331
Operating income−57−54−31−31
Other non-operating income (expense)5.98.92.90.6
Income tax00——
Net income attributable to shareholders−51−46−28−30
Earnings per share, basic-1.58-1.45-2.66-165.20
Earnings per share, diluted-1.58-1.45-2.66-165.20
Shares, weighted average (basic)3231100.2
Shares, weighted average (diluted)3231100.2
Balance sheet
Cash and cash equivalents3576750.2r
Short-term investments78752032
Other current assets0.20.20.10.0r
Current assets1161539733
Right-of-use (leased) assets0.10.10.10.2
Total assets1161609733
Accounts payable1.31.40.21.1
Current liabilities5.14.55.75.3
Lease liabilities (non-current)0——0.1
Total liabilities5.14.55.75.4
Retained earnings−346−295−250−222
Shareholders' equity11115691−187
Total liabilities and equity1161609733
Shares outstanding———0.2
Cash-flow statement
Share-based compensation6.45.35.01.9
Cash from operating activities−46−42−24−24
Cash from investing activities4.6−6213−32
Shares issued0106——
Cash from financing activities0.310586−0.1
Report10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Sagimet Biosciences Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 5 · Material agreement 3 · Agreement ended 1 · Shareholder vote 2 · Results announced 9

Sagimet Biosciences Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Material agreementAgreement ended8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

7 private funding rounds before listing

Private share sales · funding history

Private share sales of Sagimet Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$69 MNo. 7$50 to $250 million13equitySEC
Feb 2019$35 MNo. 6$10 to $50 million19equitySEC
Jun 2016$5 MNo. 5$2 to $10 million7equity, debtSEC
Oct 2014$14 MNo. 4$10 to $50 million12equitySEC
Jun 2013$8 MNo. 3$2 to $10 million2equity, optionsSEC
Nov 2011$20 MNo. 2$10 to $50 million3equity, optionsSEC
Jul 2009$15 MNo. 1$10 to $50 million4equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Discuss Sagimet Biosciences Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Sagimet Biosciences Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $19 million.

  • Mutual funds: 89 funds hold $96 millionautomatic update · Jul 31, 2026

    89 mutual funds in 1 country hold shares of Sagimet Biosciences Inc. worth $96 million, about 13.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 76 funds added shares and 0 sold; on balance they bought $64 million. Share splits are not counted as trading.

How Sagimet Biosciences Inc. compares in Biotechnology

  • Market cap$744 M · higher than 63% of 726
  • Price / book6.7× · lower than 24% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Sagimet Biosciences Inc.🇺🇸$744 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Sagimet Biosciences Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Sagimet Biosciences Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Sagimet Biosciences Inc.? Suggest a correction